Shares of Better Therapeutics, Inc. (Nasdaq: BTTX) surged over 20% in after-hours trading as the company received authorization from the FDA for its groundbreaking prescription-only digital therapeutic, AspyreRx. This innovative treatment offers cognitive behavioral therapy to adults with type 2 diabetes (T2D).

Set to be commercially launched in Q4 2023, AspyreRx is the first prescription digital behavioral therapeutic device that delivers a novel form of cognitive behavioral therapy through a smartphone.

$BTTX was trading at $1.15 in after-hours, up $0.25 (27.77%) following the announcement.

In other news, WD-40 Company (Nasdaq: WDFC) released its third-quarter fiscal 2023 financial results, reporting earnings per share (EPS) of $1.38 and revenue of $141.72 million. These figures surpassed the consensus estimates of $1.22 for EPS and $138.41 million for revenue.

The company reaffirmed its guidance for the full-year fiscal 2023, expecting diluted EPS to be in the range of $4.80 to $5.00. This aligns with market expectations, with the consensus estimate at $4.90 for the period.

In after-hours, $WDFC was trading at $201.75, showing an increase of $7.95 (4.10%).

Meanwhile, E2open Parent Holdings, Inc. (NYSE: ETWO) reported first-quarter fiscal 2024 earnings per share (EPS) of $0.05, in line with the consensus estimate.

The company reaffirmed its full-year 2024 guidance, expecting revenue in the range of $655 million to $670 million. This outlook is consistent with analysts' projections, with the consensus estimate at $663.95 million.

$ETWO was trading at $6.12, up $0.43 (7.56%) in after-hours.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)